Italy’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. The company will ask the agency to lift the hold by screening patients for hidden heart-rhythm disorders, including with genetic tests.
Newron Pharmaceuticals has secured up to €38mn to advance Phase III trials of evenamide, a drug that, if successful, could represent one of the first circuit-modulating therapies in schizophrenia.
Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568.
Nxtera Pharma Ltd